Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. - Wikidata - wikimedia - TriplyDB

Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.

Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.

http://www.wikidata.org/entity/Q36882276

about

KASL clinical practice guidelines: management of chronic hepatitis B Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines Establishment of a new quantitative detection approach to adefovir-resistant HBV and its clinical application.Management of chronic hepatitis B with nucleoside or nucleotide analogues: a review of current guidelines Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals Current status of antiviral therapy for hepatitis B Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at week 24.52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice.Response-guided treatment of cirrhotic chronic hepatitis B patients: multicenter prospective study New approaches in the management of chronic hepatitis B: role of tenofovir.Virological response to adefovir monotherapy and the risk of adefovir resistance Performance characteristics and comparison of Abbott and artus real-time systems for hepatitis B virus DNA quantification HBV and HCV therapy.Factors predicting the efficacy of adefovir dipivoxil on treatment-naïve chronic hepatitis B patients at 48 weeks.The Efficacy and Safety of Entecavir and Interferon Combination Therapy for Chronic Hepatitis B Virus Infection: A Meta-Analysis.Effect and Predictive Elements for 52 Weeks' Telbivudine Treatment on Naïve HBeAg positive Chronic Hepatitis B.Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B.Therapy for HBV Infection in Hemodialysis Patients: Is it Possible?Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B.Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir Hepatitis B Virus Genotype B and High Expression of Interferon Alpha Receptor β Subunit are Associated With Better Response to Pegylated Interferon Alpha 2a in Chinese Patients With Chronic Hepatitis B Infection.Improved Efficacy of a pegylated interferon-α-2a stepwise optimization treatment strategy in the treatment of hepatitis B e antigen-positive chronic hepatitis B patients.KASL Clinical Practice Guidelines: Management of chronic hepatitis B.The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country.Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy Characterization of a new sensitive PCR assay for quantification of viral DNA isolated from patients with hepatitis B virus infections On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B Evaluation of the dynamic pattern of viral evolution in patients with virological breakthrough during treatment with nucleoside/nucleotide analogs by ultra‑deep pyrosequencing.Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: a meta-analysis.Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B.Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life.Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B.The Association of Pre-S/S Gene Mutations and Hepatitis B Virus Vertical Transmission Hepatitis B virus infection in US correctional facilities: a review of diagnosis, management, and public health implications.Monitoring during and after antiviral therapy for hepatitis B.Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis.Current approaches for treating chronic hepatitis B: when to start, what to start with, and when to stop.Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48.

P2860

Q26752475-FA335259-D121-4B02-9874-B07E5831C003 Q27000080-DC009001-B07D-4281-8BEC-3B607A112847 Q33730282-E2DCFEC7-A9C8-4FFA-BA85-9851EDCFB015 Q33855708-4DF5AD4F-F3E8-475C-8B83-CEA21439525E Q34052838-E160019A-3A77-40A1-88D5-7413B9C7EB27 Q34408879-FE30E75E-7E1B-400F-993C-6F8A29F1025D Q34509494-39CD9033-7F39-4AB4-920E-D82CD6A4454F Q34579911-EEB9692B-9666-4CC8-BF63-FAD0809479C9 Q34805931-634793FF-C568-42C1-B3CF-1CC506D1141E Q34974141-A68E358D-FB3C-411F-B733-ECDE701A913F Q35026531-146BA4A7-1423-4125-8181-4B278E4AE254 Q35185125-75B65AD6-7BC8-4E51-BEBA-4854FF39EF6E Q35192257-D5E6763E-AB90-4BA5-B74F-0A6AAC21E320 Q35259824-6091DD0D-CA86-44D6-B1D9-B356B1A92201 Q35619167-71AA0E0B-382C-49AC-A7D7-20FE727C26CF Q35726960-B0873C43-EA8E-41DA-A1AA-585F39A11FA6 Q35764215-5447ADD6-9AE7-4C8D-9F20-7FF1CA5C944E Q35833216-698C9E63-5204-45BA-88F5-12B4ECFA0E50 Q35920128-CF446716-A964-408B-94AD-1DC8894FAEC0 Q35973806-0A8261F9-21D1-4DBF-A980-5CF3FD65716B Q36018658-15A8BD8B-874F-4777-BD30-AC1B80015169 Q36075051-65C6E5C4-A8F1-466A-A6C9-6F2C0AD42F01 Q36153775-A54CD6F8-4EB5-498C-BACD-77B41A548CAA Q36153966-32FD5F43-C77C-40E3-8A64-7EF01D2C522F Q36189795-2C80FCA7-9FF4-4E8B-8C9A-9981B440A2D8 Q36290412-479842E9-9404-468A-BF24-1B38FAED4F3D Q36314573-7607F8C7-99C4-4594-B7AE-93F502D79622 Q36325645-21BCFC6A-F13F-45A0-9330-FA7D83BB5C88 Q36390330-8E13A4C7-0CC8-47C9-8DB0-00CC9D0D657C Q36410410-7E4A6CA8-9584-47FE-9699-2EBD3DEB4097 Q36492636-7DF8FDCB-B21B-434D-BACA-E571AD768861 Q36663401-FEA85F42-ECCF-439C-AD85-2D2FD6AC16C5 Q36745002-2F04ED26-5326-4E07-89AD-ED165D582834 Q36926121-B22F6E66-7ED4-4C79-9784-4B2630EF8B6B Q37111786-7F681C6D-C369-4900-A8DC-49F2551BFAC4 Q37186162-BEC3987B-2758-4FB2-89E1-0ED3D35A38AA Q37241634-58528B86-31F9-423E-BFCE-6B0BA9CA30F8 Q37278097-2C6B474B-DBC6-4789-954B-F16C2D67B5E6 Q37334120-2F34A084-5A87-4115-90F9-50453C69EC7A Q37380067-759023C8-FB0D-4319-978B-BA7BDF2F7FE3

P2860

Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.

http://www.wikidata.org/entity/Q36882276

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Report of an international wor ...... erapy for chronic hepatitis B.

@en

type

label

Report of an international wor ...... erapy for chronic hepatitis B.

@en

prefLabel

Report of an international wor ...... erapy for chronic hepatitis B.

@en

P1433

Q36882276-164381A7-D691-42C2-96D5-CE8DA8CBA9D1

P1476

Q36882276-5D48ACC9-1CEA-4BF6-9D67-8538375606E5

P2093

Q36882276-04110D37-27A8-4B24-BE02-B5C55ECECBE8

Q36882276-33974821-4A21-4879-84E1-34A5C66D6455

Q36882276-45D36ADB-4101-4D19-81B0-46EADFF833C0

Q36882276-56FD0887-ADA4-4B4B-83AE-E22A30489488

Q36882276-5CBA9EAC-3572-4864-BBD0-627B581C8793

Q36882276-77579876-7DAB-4303-BBB6-783CE06D3D97

Q36882276-7CEBD8E6-1131-4363-8E1F-8884590F2B10

Q36882276-A3486F5B-47F7-45FF-9236-210239FE571E

Q36882276-B9937D40-1FAE-432B-B11C-C0E89A1A0DFD

Q36882276-C67E27A4-90FF-4F01-A331-EDD27E8F3A09

P304

Q36882276-BA6F14C1-5385-45B3-A33A-DC9AE2550658

P31

Q36882276-C2356308-6732-44E0-9F92-F6322239DB12

P356

Q36882276-BABF16B7-4D27-422D-8800-4CCBDC70D972

P407

Q36882276-4924E6DE-E16F-45B8-8F21-CA73877048BC

P433

Q36882276-F095B9F7-81A0-4BFD-8A58-A56FD61CF262

P478

Q36882276-68AB4C19-47AF-4BEF-BBEF-4E221F036B97

P50

Q36882276-41B82283-AA44-4B78-BB6F-3E521EF79BD2

P577

Q36882276-B0F000EC-7D34-47D8-A8C3-A2734D3582A4

P5875

Q36882276-BA900032-6D31-42F2-88F4-16A776B872A1

P698

Q36882276-8411160F-0A4F-4FE0-AB19-057A6BBF1309

P921

Q36882276-6505F4C1-655D-47EC-9404-F680DD80D0B4

P356

J.CGH.2007.05.004

P1433

Clinical Gastroenterology and Hepatology

P1476

Report of an international wor ...... erapy for chronic hepatitis B.

@en

P2093

Douglas T Dieterich

http://www.w3.org/2001/XMLSchema#string

Edward J Gane

http://www.w3.org/2001/XMLSchema#string

Emmet B Keeffe

http://www.w3.org/2001/XMLSchema#string

Fabien Zoulim

http://www.w3.org/2001/XMLSchema#string

Ira M Jacobson

http://www.w3.org/2001/XMLSchema#string

Nikolai Naoumov

http://www.w3.org/2001/XMLSchema#string

Patrick Marcellin

http://www.w3.org/2001/XMLSchema#string

Rafael Esteban-Mur

http://www.w3.org/2001/XMLSchema#string

Raymond S Koff

http://www.w3.org/2001/XMLSchema#string

Seng G Lim

http://www.w3.org/2001/XMLSchema#string

P304

890-897

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CGH.2007.05.004

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-07-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6206423

http://www.w3.org/2001/XMLSchema#string

P698

17632041

http://www.w3.org/2001/XMLSchema#string

P921